Premium
Reactivity of in vitro activated human T lymphocytes to p ‐phenylenediamine and related substances
Author(s) -
Skazik Claudia,
Grannemann Silke,
Wilbers Liane,
Merk Hans F.,
Coenraads PieterJan,
Breuer Sebastian,
Blömeke Brunhilde
Publication year - 2008
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/j.1600-0536.2008.01416.x
Subject(s) - peripheral blood mononuclear cell , reactivity (psychology) , epitope , polyclonal antibodies , t cell receptor , in vitro , sensitization , cross reactivity , chemistry , t cell , monoclonal antibody , microbiology and biotechnology , immunology , antigen , biology , medicine , biochemistry , cross reactions , antibody , pathology , alternative medicine , immune system
Background: Patch tests to p ‐phenylenediamine (PPD) and related substances often show concurrent reactions that can be attributed to separate sensitization or cross‐reactivity. Objectives: In order to understand the health risks associated with cross‐reactivity, we studied cross‐reactivity of eight chemicals in vitro by measurement of T‐cell proliferation of peripheral blood mononuclear cells (PBMC), T‐cell lines (TCL), and T‐cell clones (TCC) of subjects with a positive patch test result to PPD. Patients/Methods: We studied PBMC from 13 patients and were able to generate TCL from seven and TCC from four patients. Their proliferative responses to the chemicals were estimated. Results: Concurrent reactions to these compounds on the polyclonal and monoclonal level were found. A restricted T‐cell receptor (TCR) Vβ16‐usage was observed (5/8 clones). A detailed analysis of 34 TCL showed broad cross‐reactivity (64.7%) between PPD, p ‐toluenediamine, Bandrowski’s Base, and p ‐aminoazobenzene. More restricted patterns were found in 8.8%, which responded only to compounds with two or three benzene rings, whereas 26.5% of the clones reacted specifically only to one compound. Conclusion: More than 60% of the clones showed a broad cross‐reactivity pattern. Hence, clinically observed cross‐reactivity between different para‐amino compounds can be based on a TCR recognizing similar epitopes of these compounds with low specificity.